TY - JOUR
T1 - Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
AU - Chen, Hong Hwa
AU - Chen, William Tzu Liang
AU - Lee, Hsin Chung
AU - Lin, Jen Kou
AU - Fang, Chuan Yin
AU - Chou, Yenn Hwei
AU - Lin, Peng Chan
AU - Lin, Bo Wen
AU - Huang, Chi Chou
AU - Yeh, Chung Hung
AU - Hsu, Hsi Hsien
AU - Chen, Hung Chang
AU - Ting, Wen Chien
AU - Yang, Ming Chin
AU - Tan, Elise Chia Hui
N1 - Funding Information:
This study was supported by funding from Roche Products Ltd. However, the work and opinions presented in this manuscript are solely those of the authors.
Publisher Copyright:
© 2014, Springer International Publishing Switzerland.
PY - 2015/2
Y1 - 2015/2
N2 - Purpose: The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. Methods: We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics. Results: A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P = 0.024; final, P = 0.013), appetite loss (mid-term, P < 0.0001; final, P = 0.001), and fewer side effects from chemotherapy (mid-term, P = 0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient]. Conclusions: Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer.
AB - Purpose: The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients. Methods: We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics. Results: A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P = 0.024; final, P = 0.013), appetite loss (mid-term, P < 0.0001; final, P = 0.001), and fewer side effects from chemotherapy (mid-term, P = 0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient]. Conclusions: Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=84931092110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931092110&partnerID=8YFLogxK
U2 - 10.1007/s11136-014-0773-x
DO - 10.1007/s11136-014-0773-x
M3 - Article
C2 - 25099199
AN - SCOPUS:84931092110
SN - 0962-9343
VL - 24
SP - 473
EP - 484
JO - Quality of Life Research
JF - Quality of Life Research
IS - 2
ER -